Australia, Jan. 21 -- GENUITI THERAPEUTICS Inc., owns the trademark (2496455) for 'GENUITI' till Nov. 6, 2034.
Status: registered:
Registered/protected
Classes: 5 [Therapeutic pharmaceuticals for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical preparations for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceuticals comprising small molecules for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes], 42 [Scientific research for medical purposes in the fields of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development of therapeutics for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of small molecule drug discovery; medical and scientific research in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products development in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; drug discovery services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical research and development services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of precision medicine], 5 [therapeutic pharmaceuticals for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical preparations for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceuticals comprising small molecules for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes] and 42 [scientific research for medical purposes in the fields of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development of therapeutics for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of small molecule drug discovery; medical and scientific research in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products development in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; drug discovery services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical research and development services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of precision medicine]
Type of Mark: Word
Date of Acceptance: Nov. 11, 2024
Registration Advertised: Jan. 20
For further details contact Davies Collison Cave Pty. Ltd. .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2496455.
Disclaimer: Curated by HT Syndication.
